This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conrads, G.
Right arrow Articles by Goldstein, E. J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conrads, G.
Right arrow Articles by Goldstein, E. J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2005, p. 434-437, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.434-437.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Genetic Determinant of Intrinsic Quinolone Resistance in Fusobacterium canifelinum

Georg Conrads,1,2* Diane M. Citron,1 and Ellie J. C. Goldstein1

R. M. Alden Research Laboratory, Santa Monica, California,1 Lehr- und Forschungsgebiet Orale Mikrobiologie und Immunologie der Klinik für Zahnerhaltung, Parodontologie und Präventive Zahnerhaltung und Institut für Medizinische Mikrobiologie, Universitätsklinikum (RWTH), Aachen, Germany2

Received 25 June 2004/ Returned for modification 12 September 2004/ Accepted 23 September 2004

Fourteen fluoroquinolone-resistant fusobacterial strains, originating from cats or dogs, were characterized by sequencing of the 16S-23S and 16S rRNA genes and DNA-DNA hybridization and were described as a new species, Fusobacterium canifelinum. All of the strains are intrinsically resistant (MIC, >4 g/ml) to levofloxacin and other fluoroquinolones. Compared to the quinolone resistance-determining region (gyrA) of the susceptible relative F. nucleatum, we found that Ser79 was replaced with leucine and Gly83 was replaced with arginine.

* Corresponding author. Mailing address: Division of Oral Microbiology and Immunology University Hospital (RWTH), Pauwelsstrasse 30, D-52057 Aachen, Germany. Phone: 49-241-8088448. Fax: 49-241-8082483. E-mail: gconrads{at}ukaachen.de.

Antimicrobial Agents and Chemotherapy, January 2005, p. 434-437, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.434-437.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»